

Per Sproegel, Vice President, Medical Science at LEO Pharma said, “Thomas Hultsch comes to LEO Pharma with an extensive network within immune dermatology in the US and Europe as well as an impressive track record of initiating successful scientific collaborations. With his appointment as Head of LEO Pharma's new Translational Medicine Unit in Boston, we are ready to take translational medicine at LEO Pharma to the next level in terms of being a science driven and patient focused company.”

Thomas Hultsch is a Doctor of Medicine, a board-certified Dermatologist and Allergist and received his *venia legendi* for immunology from the Johannes Gutenberg University in Mainz, Germany. He trained as a post-doc and fellow at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland focusing on molecular biology, cell biology and clinical immunology/allergy.

Thomas Hultsch, Head of Translational Medicine, LEO Pharma, Boston said, "I am thrilled to join LEO Pharma at a time of break-through discoveries in multiple areas of skin biology and technology, providing unparalleled opportunities to drive innovation in dermatology for the benefit of patients world-wide."

He comes from a position as Senior Director for Translational Medicine at Sanofi US, where he successfully built and operationalized a translational medicine team and brings a wealth of research experience to LEO Pharma, including five years of basic research and more than 15 years of clinical research from different positions in the area of inflammatory diseases in the US and Europe.